This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Menthone is a medication used to treat stone formation in the gallbladder and liver.
- Generic Name
- Menthone
- DrugBank Accession Number
- DB15920
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Menthone (DB15920)
- Weight
- Average: 154.253
Monoisotopic: 154.1357652 - Chemical Formula
- C10H18O
- Synonyms
- DL-Menthone
- Menthone G
- External IDs
- 201-941-1
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ROWACHOL CAPSULES Menthone (6 mg) + Borneol (5 mg) + Camphene (5 mg) + Eucalyptol (2 mg) + Levomenthol (32 mg) + Olive oil (33 mg) + alpha-Pinene (17 mg) Capsule Oral DCH AURIGA (MALAYSIA) SDN. BHD. 2020-09-08 Not applicable Malaysia 
โรวาคอล Menthone (6 mg) + Borneol (5 mg) + Camphene (5 mg) + Eucalyptol (2 mg) + Levomenthol (32 mg) + alpha-Pinene (13.6 mg) + beta-Pinene (3.4 mg) Capsule บริษัท ดีซีเอช ออริกา (ประเทศไทย) จำกัด 1986-09-25 Not applicable Thailand 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9NH5J4V8FN
- CAS number
- 89-80-5
- InChI Key
- NFLGAXVYCFJBMK-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-9H,4-6H2,1-3H3
- IUPAC Name
- 5-methyl-2-(propan-2-yl)cyclohexan-1-one
- SMILES
- CC(C)C1CCC(C)CC1=O
References
- General References
- FDA Thailand: Rowachol (Borneol, Camphene, Eucalyptol, Levomenthol, Menthone, Alpha-Pinene, and Beta-Pinene) Oral Capsule [Link]
- External Links
- ChemSpider
- 6720
- ChEBI
- 36742
- ChEMBL
- CHEMBL1719455
- Wikipedia
- Menthone
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Capsule - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.265 mg/mL ALOGPS logP 2.65 ALOGPS logP 3.05 Chemaxon logS -2.8 ALOGPS pKa (Strongest Basic) -7.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 17.07 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 46.52 m3·mol-1 Chemaxon Polarizability 19.02 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at November 23, 2020 16:18 / Updated at May 07, 2021 21:08